Glenmark rises 4% on receipt of inspection report from US FDA

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Glenmark rose over 4 percent intraday on Wednesday after it received an inspection report from the US drug regulator.

The drug firm received establishment inspection report (EIR) from the US Food and Drug Administration on closure of inspection of its Ankleshwar plant in Gujarat, the company said.

"Glenmark would like to state that its Ankleshwar plant received the EIR (establishment inspection report) yesterday. The EIR is issued by the FDA only if it finds the facility to be deemed acceptable," it said in a BSE filing.

The USFDA releases a copy of the EIR to the establishment that is the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.

The stock rose over 2 percent in the past three days. At 12:25 hrs Glenmark Pharma was quoting at Rs 908.20, up Rs 17.30, or 1.94 percent, on the BSE. It touched an intraday high of Rs 929.90 and an intraday low of Rs 900.55.